[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Takemoto Y, Kawahara M, Yamamoto S, Iuchi K, Mori T, Ueda E, Tsuchiyama T, Furuse K: Synchronous primary adenocarcinoma of the lung and leiomyosarcoma of the small intestine. Intern Med; 2000 Aug;39(8):655-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous primary adenocarcinoma of the lung and leiomyosarcoma of the small intestine.
  • The occurrence of synchronous epithelial cancer of the lung and leiomyosarcoma of the small intestine is rare.
  • We report here the case of a 62-year-old man with adenocarcinoma of the lung in clinical stage IIIB (T4N0M0).
  • After two courses of chemotherapy (cisplatin, 80 mg/m2 and mitomycin C, 8 mg/m2) the patient developed symptoms of a small bowel obstruction.
  • Palliative surgical resection was performed and a leiomyosarcoma of the small intestine was found and defined by an immunohistological study.
  • The patient died of disseminated adenocarcinoma 26 months following chemotherapy.
  • [MeSH-minor] Humans. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Intestine, Small. Male. Middle Aged

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10939541.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


2. Overman MJ: Recent advances in the management of adenocarcinoma of the small intestine. Gastrointest Cancer Res; 2009 May;3(3):90-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the management of adenocarcinoma of the small intestine.
  • Adenocarcinoma of the small intestine is a rare malignancy with limited data available to guide therapeutic decisions.
  • Delays in diagnosis are frequent and the majority of patients will present with advanced-stage disease and either lymph node involvement or distant metastatic disease.
  • Furthermore, the role of adjuvant therapy in patients who undergo curative resection is unclear.
  • Recent retrospective and prospective studies have helped to clarify the optimal chemotherapy approach for advanced small bowel adenocarcinoma.
  • Further clinical studies in this rare tumor type are needed.
  • This article reviews the clinical features and evaluation of patients with small bowel adenocarcinoma and focuses on recent advances in management.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2009;39(1):27-31 [19132464.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):635-41; discussion 641-2 [10843358.001]
  • [Cites] Ann Surg. 2009 Jan;249(1):63-71 [19106677.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9274-9 [19010900.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1163-7 [18727930.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2038-45 [18759326.001]
  • [Cites] Dig Dis Sci. 2008 Aug;53(8):2140-3 [18270840.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1436-41 [17689032.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2263-9 [17549572.001]
  • [Cites] Arch Surg. 2007 Mar;142(3):285-8 [17372054.001]
  • [Cites] Radiology. 2006 Dec;241(3):796-801 [17053201.001]
  • [Cites] Gastrointest Endosc. 2006 Sep;64(3):445-9 [16923502.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):225-31 [16755174.001]
  • [Cites] World J Surg. 2006 Mar;30(3):391-8; discussion 399 [16479330.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):209; author reply 209-10 [16382129.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3761-9 [12963697.001]
  • [Cites] J Chemother. 2003 Oct;15(5):503-6 [14598944.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):925-30 [14592670.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1551-7 [12627520.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]
  • [Cites] Arch Surg. 2002 May;137(5):564-70; discussion 570-1 [11982470.001]
  • [Cites] Gut. 2002 Feb;50(2):218-23 [11788563.001]
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] Endoscopy. 2005 Oct;37(10):960-5 [16189768.001]
  • [Cites] Oncology. 2005;68(4-6):526-37 [16037686.001]
  • [Cites] Scand J Gastroenterol. 2005 Jun;40(6):725-33 [16036534.001]
  • [Cites] Oncologist. 2005 Feb;10(2):132-7 [15709215.001]
  • [Cites] Dig Liver Dis. 2004 Nov;36(11):782-3 [15571011.001]
  • [Cites] Surg Gynecol Obstet. 1956 Jan;102(1):1-38 [13299024.001]
  • [Cites] Am J Surg. 1965 Jan;109:43-6 [14248295.001]
  • [Cites] Scand J Gastroenterol. 2004 Aug;39(8):748-53 [15513360.001]
  • [Cites] Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):210-5 [9435876.001]
  • [Cites] Int J Cancer. 1999 Jul 19;82(2):171-4 [10389747.001]
  • [Cites] Br J Surg. 1999 Feb;86(2):189-93 [10100785.001]
  • [Cites] J Gastrointest Surg. 1998 Jan-Feb;2(1):79-87 [9841972.001]
  • [Cites] Br J Cancer. 1998 Aug;78(4):508-10 [9716035.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):240-4 [9669805.001]
  • [Cites] J Comput Assist Tomogr. 1997 Nov-Dec;21(6):986-91 [9386295.001]
  • [Cites] Int J Cancer. 1997 Feb 7;70(4):390-5 [9033644.001]
  • [Cites] J Am Coll Surg. 1996 Aug;183(2):89-96 [8696551.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3011-20 [8187091.001]
  • [Cites] Ann Surg Oncol. 1994 Jan;1(1):73-8 [7834432.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):183-8 [7842287.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Nov-Dec;2(6):551-3 [8268772.001]
  • [Cites] Gastrointest Radiol. 1991 Spring;16(2):115-9 [2016021.001]
  • [Cites] Am J Gastroenterol. 1991 Mar;86(3):304-8 [1998312.001]
  • [Cites] AJR Am J Roentgenol. 1989 Oct;153(4):741-4 [2672733.001]
  • [Cites] Cancer. 1990 Aug 15;66(4):702-15 [2167140.001]
  • [Cites] J Radiol. 1983 Feb;64(2):117-23 [6341573.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):66-71 [6691554.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):23-5 [6690001.001]
  • [Cites] Cancer. 1981 Aug 1;48(3):799-819 [7248908.001]
  • [Cites] Am J Surg. 1977 Sep;134(3):331-3 [900333.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] J Clin Pathol. 2003 Dec;56(12):898-903 [14645346.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):727-32 [11462914.001]
  • [Cites] Food Chem Toxicol. 2001 Mar;39(3):209-28 [11278053.001]
  • [Cites] Gastric Cancer. 2008;11(4):201-5 [19132481.001]
  • (PMID = 19626152.001).
  • [ISSN] 1934-7820
  • [Journal-full-title] Gastrointestinal cancer research : GCR
  • [ISO-abbreviation] Gastrointest Cancer Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2713134
  •  go-up   go-down


3. Kikuchi M, Kamei S, Morirama Y, Tuchiya T, Miwa K, Yokoi S, Nakano M, Ehara H, Deguchi T, Hirose Y: [Case of urachal cancer treated by neoadjuvant chemotherapy with FOLFOX4 (oxaliplatin, 5-FU and leukovolin)]. Hinyokika Kiyo; 2008 Aug;54(8):557-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of urachal cancer treated by neoadjuvant chemotherapy with FOLFOX4 (oxaliplatin, 5-FU and leukovolin)].
  • A 52-year-old woman was referred to our hospital for treatment of urachal cancer.
  • Computed tomography and magnetic resonance imaging showed a non-papillary sessile tumor, which was located on the dome of the bladder and invaded the small intestine.
  • The tumor was diagnosed as Sheldon's stage IIIC urachal cancer.
  • After three courses of neoadjuvant chemotherapy with FOLFOX4 (oxaliplatin, 5-FU and leukovolin), the tumor was reduced from 7 x 6 cm to 5.5 x 5 cm in size.
  • One course of adjuvant chemotherapy (FOLFOX4) was performed.
  • The surgical margins were negative for the cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Ileal Neoplasms / drug therapy. Neoadjuvant Therapy. Urachus. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Middle Aged. Neoplasm Invasiveness. Organoplatinum Compounds / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Urachal cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788447.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


Advertisement
4. Higashi D, Ishibashi Y, Tamura T, Nii K, Egawa Y, Koga M, Tomiyasu T, Harimura T, Tanaka R, Futatsuki R, Noda S, Futami K, Maekawa T, Takaki Y, Hirai F, Matsui T: Clinical features of and chemotherapy for cancer of the small intestine. Anticancer Res; 2010 Aug;30(8):3193-7
Genetic Alliance. consumer health - Small intestine cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of and chemotherapy for cancer of the small intestine.
  • BACKGROUND: Cancer of the small intestine is a rare disease, and its clinical features have not been clearly elucidated.
  • Techniques such as double balloon endoscopy and capsule endoscopy allow the preoperative diagnosis of cancer of the small intestine, but this cancer is often detected at an advanced state and in many cases postoperative chemotherapy is required.
  • This study evaluated the pre- and postoperative clinical course of cancer of the small intestine and the effectiveness of chemotherapy.
  • PATIENTS AND METHODS: Patients who underwent surgery for cancer of the small intestine in this Department from July 1985 to December 2008 were included in this study.
  • Duodenal cancer has vastly different origins, methods of diagnosis, and surgical procedures, so this form of cancer was excluded.
  • There were 8 cases of jejunal or ileal cancer treated during the study period.
  • The pre- and postoperative course of these cases was reviewed, as well as the effectiveness of chemotherapy in cases of recurrence.
  • Six patients underwent a partial resection of the small intestine, and a right hemicolectomy, and a bypass were performed in one case each.
  • The tumor type according to Borrmann's classification indicated that 5 tumors were type 2, 2 were type 3, and 1 was type 5; the mean tumor size was 6.3±5.3 (2.5-18.0) cm.
  • TNM staging indicated that 3 tumors were stage II, 1 was stage III, and 4 were stage IV.
  • Six patients underwent postoperative chemotherapy.
  • One patient underwent adjuvant chemotherapy of, and 5 patients with recurring or advanced cancer underwent therapeutic chemotherapy of.
  • The course of chemotherapy for the 5 patients with recurrent or advanced cancer resulted in 4 patients with progressive disease (PD) and 1 with stable disease (SD).
  • CONCLUSION: The basic treatment for cancer of the small intestine is surgical resection.
  • Palliative surgery and chemotherapy are considered in cases where resection is not possible or the cancer recurs.
  • Nevertheless, there is no established regimen for such chemotherapy.
  • Cancer of the small intestine is currently being treated with chemotherapy based on the treatment strategies for colon cancer, but there are few reports of its success.
  • Chemotherapy was unsuccessful in treating any of the patients with recurring or advanced cancer reviewed in this report.
  • The diagnosis must therefore be improved and postoperative chemotherapy will be needed to treat cancer of the small intestine given its increasing incidence, and therefore physicians are working as quickly as possible to establish an optimal treatment regimen.
  • [MeSH-major] Intestinal Neoplasms / drug therapy. Intestine, Small / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871040.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


5. Kini S, Kapadia RM, Amarapurkar A: Intussusception due to intestinal metastasis from lung cancer. Indian J Pathol Microbiol; 2010 Jan-Mar;53(1):141-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intussusception due to intestinal metastasis from lung cancer.
  • Intestinal metastasis from lung primary is very uncommon and seen at the terminal stage of the disease.
  • A computerized tomography (CT)--scan abdomen showed mural thickening of short loop of jejunum with ileoileal intussusception.
  • Resection-anastomosis revealed two separate nodules in the small intestine.
  • The patient, a diagnosed case of primary carcinoma of lung seven months ago, had been treated with one cycle of chemotherapy.
  • Histopathology of the small intestinal nodules showed features of adenocarcinoma consistent with the known primary lung cancer.
  • We present this case to arouse a clinical suspicion of intestinal metastasis in known cases of primary lung cancer presenting with the sudden onset of abdominal complaints.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090247.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


6. Okuda M, Nomura J, Tateno H, Kameoka J, Sasaki T: CD56 positive intestinal T-cell lymphoma: treatment with high dose chemotherapy and autologous peripheral blood stem cell transplantation. Intern Med; 2002 Sep;41(9):734-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD56 positive intestinal T-cell lymphoma: treatment with high dose chemotherapy and autologous peripheral blood stem cell transplantation.
  • A 63-year-old man presented with a perforation of the small intestine.
  • A diagnosis of intestinal T-cell lymphoma (ITCL) was made from CD (cluster differentiation) 3 positivity and a rearrangement of T-cell receptor genes.
  • Although the prognosis of ITCL has been considered to be very poor irrespective of CD56 positivity, complete remission was achieved in this case by high dose chemotherapy followed by autologous peripheral blood stem cell transplantation (auto-PBSCT) even after relapse.
  • Auto-PBSCT in the earlier stage of the disease might improve the prognosis.
  • [MeSH-major] Antigens, CD56 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / therapy. Lymphoma, T-Cell / therapy. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Combined Modality Therapy. Humans. Intestinal Perforation / pathology. Intestinal Perforation / radiography. Intestinal Perforation / surgery. Male. Middle Aged. Remission Induction / methods. Tomography, X-Ray Computed. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12322803.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


7. Kummar S, Ciesielski TE, Fogarasi MC: Management of small bowel adenocarcinoma. Oncology (Williston Park); 2002 Oct;16(10):1364-9; discussion 1370, 1372-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of small bowel adenocarcinoma.
  • Small bowel adenocarcinoma is a relatively rare malignancy.
  • Only limited information is available on the incidence, prognosis, and role of chemotherapy in the treatment of this disease.
  • We present a review of currently available clinical data to assist the practicing oncologist in the treatment of these patients.
  • Approximately 5,300 new cases and 1,100 deaths from small bowel adenocarcinoma are reported annually in the United States.
  • Increased incidence is seen in patients with Crohn's disease, hereditary nonpolyposis colorectal cancer, and familial adenomatouspolyposis.
  • Factors associated with poor prognosis are age > 75 years, lack of surgical resection, advanced stage, and tumor arising in the duodenum.
  • Few data exist on the use of (neo)adjuvant or palliative chemo(radio)therapy in this setting.
  • Fluorouracil (5-FU)based chemotherapy, as a single agent or in combination with others, has been used in most case series.
  • Duodenal adenocarcinoma accounts for more than 50% of all cases of small bowel adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Intestinal Neoplasms / drug therapy. Intestine, Small

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12435206.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


8. Nagashima Y, Okamoto H, Narita Y, Hida N, Naoki K, Kunikane H, Watanabe K: [Perforation of the small intestine caused by metastasis from primary lung cancer: report of two cases and the discussion of 48 cases published in the Japanese literature]. Nihon Kokyuki Gakkai Zasshi; 2007 May;45(5):430-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Perforation of the small intestine caused by metastasis from primary lung cancer: report of two cases and the discussion of 48 cases published in the Japanese literature].
  • Case 1 was a 62-year-old man who had performance status (PS) of 1 and stage IIIB adenocarcinoma of the lung.
  • As a result of computed tomography of the abdomen.
  • An operation was undertaken and the surgical findings showed perforation by small intestine metastasis from lung adenocarcinoma.
  • Case 2 was a 54-year-old man who had a PS of 3 and stage IV large cell carcinoma.
  • After chemotherapy and sequential cranial radiotherapy, he developed anemia of unknown cause.
  • He underwent surgery and the surgical findings showed a metastasis of large cell carcinoma in the small intestine.
  • 48 operated cases with perforation caused by small intestine metastasis of lung cancer have been reported in full-length papers.
  • Although the postoperative median survival time was 48 days, only one surgery-related death occurred.
  • Patients who had a history of prior cancer treatment before surgery tended to achieve more prolonged survival compared to those who had not cancer treatment, probably due to poor PS.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / secondary. Intestinal Neoplasms / secondary. Intestinal Perforation / etiology. Intestine, Small. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Small intestine cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17554989.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 5
  •  go-up   go-down


9. Takada J, Katsuki Y, Hamada H, Tsuji Y: [Two cases of inoperable gastric cancer successively treated with TS-1+CDDP as neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1897-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of inoperable gastric cancer successively treated with TS-1+CDDP as neoadjuvant chemotherapy].
  • CASE 1: A 30-year-old male with a loss of appetite and hematemesis was diagnosed with scirrhous gastric cancer upon detailed examination.
  • Pre-operative diagnosis was T3N3P1HOM1, Stage V.
  • Three courses of pre-operative chemotherapy (NAC) of TS-1+CDDP were performed.
  • Total gastrectomy, resection of the small intestine and cholecystectomy were performed.
  • Pathological findings were type 4, por 2, pT3 (ss), ly1, v0, pN0, pM1 (gall bladder, small intestine): pStage IV.
  • CASE 2: A 55-year-old male with epigastric pain was diagnosed with scirrhous gastric cancer upon detailed examination.
  • Pre-operative diagnosis was T3N1P1H0M0, Stage IIIA.
  • A clear reduction of tumor size was noted upon laparoscopic examination as well as imaging and distal gastrectomy was performed.
  • The pathological findings shown were type 4, por 2, pT3 (ss), ly2, v1, pN1, p1, pStage IV.
  • The prognosis for inoperable gastric cancer is not promising and there is no established treatment guideline, however, there are cases in which TS-1+CDDP therapy has made surgery possible, and with the anticipation of extended survival, can be considered a useful therapy method.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Anastomosis, Surgical. Cholecystectomy. Cisplatin / administration & dosage. Gastrectomy. Humans. Intestine, Small / surgery. Jejunum / surgery. Male. Middle Aged. Neoadjuvant Therapy. Stomach / surgery. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212140.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Ogata Y, Yamaguchi K, Sasatomi T, Uchida S, Akagi Y, Shirouzu K: [Treatment and outcome in small bowel cancer]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1454-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and outcome in small bowel cancer].
  • In adenocarcinoma of the small intestine, delays in diagnosis are frequent, and the majority of patients present with advanced- stage disease and either lymph node involvement or distant metastatic disease.
  • Surgical resection is a mainstay in treatment of this disease, but the role of adjuvant therapy is unclear.
  • Recent retrospective and prospective studies have helped to clarify the optimal chemotherapy approach for advanced small bowel adenocarcinoma.
  • Further clinical studies on this rare type of tumor are needed.
  • The 72nd Japanese Society for Cancer of the Colon and Rectum have conducted a retrospective review of Japanese patients with adenocarcinoma of the jejunum or ileum.
  • The data indicated that although not statistically significant, there was a trend in median overall survival favoring the chemotherapy for advanced jejunal or ileal adenocarcinoma (17 months vs. 8 months, p=0.114).
  • [MeSH-major] Adenocarcinoma / therapy. Intestinal Neoplasms / therapy. Intestine, Small
  • [MeSH-minor] Combined Modality Therapy. Humans. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716869.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


11. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA: Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol; 2010 May;49(4):474-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine.
  • BACKGROUND: The benefit of adjuvant therapy for resected small bowel adenocarcinoma has not been proven.
  • We undertook a retrospective analysis to evaluate the benefit of adjuvant therapy in a clearly defined patient population with curatively resected small bowel adenocarcinoma.
  • MATERIAL AND METHODS: We identified 54 patients with small bowel adenocarcinoma who underwent margin-negative surgical resection and were evaluated after surgery at the University of Texas, M. D.
  • Anderson Cancer Center between 1990 and 2008.
  • Thirty patients (56%) received adjuvant therapy consisting of systemic chemotherapy with or without radiation in 28 and radiation alone in two.
  • Patients who received adjuvant therapy had significantly higher tumor stage and rate of lymph node involvement.
  • Five-year DFS and OS did not differ between treatment groups.
  • In multivariate analysis, the use of adjuvant therapy was associated with improved DFS (HR 0.27; 95% CI 0.07-0.98, P = 0.05) but not OS (HR 0.47; 95% CI 0.13-1.62, P = 0.23).
  • In patients with a high risk of relapse (defined as a lymph node ratio >or=10%), adjuvant therapy appeared to improve OS, P = 0.04, but not DFS, P = 0.15.
  • DISCUSSION: The use of adjuvant therapy for curatively resected small bowel adenocarcinoma was associated with an improvement in DFS.
  • This finding strongly supports further investigation of adjuvant chemotherapy in this tumor type.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / therapy. Intestine, Small
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Chemotherapy, Adjuvant. Disease-Free Survival. Duodenal Neoplasms / therapy. Female. Follow-Up Studies. Humans. Ileal Neoplasms / therapy. Jejunal Neoplasms / therapy. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20397775.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


12. Nakajima J, Sasaki A, Otsuka K, Obuchi T, Nishizuka S, Wakabayashi G: Risk factors for early postoperative small bowel obstruction after colectomy for colorectal cancer. World J Surg; 2010 May;34(5):1086-90
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for early postoperative small bowel obstruction after colectomy for colorectal cancer.
  • BACKGROUND: Small bowel obstruction (SBO) after colectomy leads to markedly lower patient quality of life, longer hospital stays, and increased hospitalization costs.
  • From a systemic treatment point of view, early postoperative SBO is one of the major concerns of the surgery because it often delays chemotherapy in advanced cases.
  • METHODS: Univariate and multivariate analyses were performed for 1,004 patients who underwent open colectomy (OC, 421 patients) or laparoscopic-assisted colectomy (LAC, 583 patients) for colorectal cancer between January 1997 and December 2008.
  • Univariate analysis of the risk factors for early postoperative SBO showed no statistical significance between respective risk factors and occurrence of SBO for age >70 years, body mass index >25 kg/m(2), ASA score > or =3, pT stage T4, pN stage > or =N1, pM stage M1, or increased blood loss.
  • Multivariate analysis demonstrated that OC (odds ratio (OR), 2.62; 95% confidence interval (CI), 1.34-5.13; P = 0.005), and rectal cancer (OR, 2.12; 95% CI, 1.1-4.1; P = 0.025) were independent risk factors for postoperative SBO after colectomy for colorectal cancer.
  • CONCLUSIONS: Early postoperative SBO cases are more likely to occur with OC and rectal cancer.
  • LAC is an effective surgical procedure from the perspective of reducing the incidence of early postoperative SBO after colectomy for colorectal cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Intestine, Small. Laparoscopy. Male. Middle Aged. Risk Factors. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2006 Mar;93(3):300-8 [16363014.001]
  • [Cites] Surg Endosc. 2003 Apr;17(4):636-40 [12574925.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Ann Surg. 1989 Aug;210(2):216-9 [2757422.001]
  • [Cites] Langenbecks Arch Surg. 1998 Mar;383(1):49-55 [9627171.001]
  • [Cites] Colorectal Dis. 2002 Sep;4(5):355-360 [12780581.001]
  • [Cites] Br J Surg. 2006 Feb;93(2):195-204 [16392101.001]
  • [Cites] J Gastrointest Surg. 2008 May;12(5):926-32 [18060466.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] Lancet. 1999 May 1;353(9163):1476-80 [10232313.001]
  • [Cites] World J Surg. 2008 Oct;32(10):2287-92 [18642044.001]
  • [Cites] JAMA. 2002 Jan 16;287(3):321-8 [11790211.001]
  • [Cites] Arch Surg. 1998 Mar;133(3):258-62 [9517736.001]
  • [Cites] Ann Surg. 1973 Dec;178(6):781-6 [4759410.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2217-23 [16228828.001]
  • [Cites] Gut. 2000 Dec;47 Suppl 4:iv85-6; discussion iv87 [11076929.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):759-66; disscussion 767 [12454514.001]
  • [Cites] Surg Endosc. 2003 Jul;17(7):1017-22 [12632122.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Apr;13(2):88-94 [12709613.001]
  • [Cites] Ann Surg. 1998 Nov;228(5):652-63 [9833803.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Br J Surg. 2008 Jul;95(7):909-14 [18509861.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):343-50 [12616117.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):378-87 [10419919.001]
  • [Cites] Langenbecks Arch Surg. 2004 Aug;389(4):250-5 [15103466.001]
  • [Cites] Eur J Surg. 1998 Aug;164(8):587-92 [9720935.001]
  • (PMID = 20151126.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Cao J, Zuo Y, Lv F, Chen Z, Li J: Primary small intestinal malignant tumors: survival analysis of 48 postoperative patients. J Clin Gastroenterol; 2008 Feb;42(2):167-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small intestinal malignant tumors: survival analysis of 48 postoperative patients.
  • BACKGROUND: Primary small intestinal malignant tumor is relatively uncommon compared to gastric and colorectal cancer.
  • GOALS: To analyze the relationship between the prognoses, histologic type, and therapeutic strategy in postoperative patients with small intestinal tumor.
  • STUDY: The parameters that affect survival were evaluated using multivariate Cox analysis in 48 cases of small intestinal tumor (confirmed by operation and pathology) for the past 10 years.
  • The median OS for all the 20 stage II/III patients who received adjuvant chemotherapy was 28 months, whereas the median OS for the 15 patients who did not receive the therapy was 37 months (P=0.276).
  • The median time to progression for 8 patients with adenocarcinoma who received 5-fluorouracil or platinum-based palliative chemotherapy was 7 months, whereas for the patients who did not receive the therapy it was 3 months (P=0.06).
  • The result of multivariate analyses showed that only the clinical stage was significantly correlated with OS (P<0.001).
  • CONCLUSIONS: The prognosis for small intestinal malignancies is associated with clinical stage, and palliative chemotherapy with a 5-fluorouracil or platinum-based regimen offers a potential benefit to patients with adenocarcinoma.
  • Postoperative adjuvant chemotherapy seems to hold no therapeutic or survival benefit for patients with primary small bowel malignancies.
  • [MeSH-major] Intestinal Neoplasms / mortality. Intestinal Neoplasms / surgery. Intestine, Small / pathology
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Male. Middle Aged. Platinum / therapeutic use. Prognosis. Proportional Hazards Models. Survival Analysis

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18209587.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 49DFR088MY / Platinum; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Kotake M, Murakami N, Bandou H, Morita K, Koizumi H, Yoshino H, Tawaraya K, Ishiguro K, Kinoshita S, Yamada T: [A case of primary small intestinal cancer accompanied by virchow lymph node metastasis undergoing TS-1 treatment]. Gan To Kagaku Ryoho; 2005 Nov;32(12):1955-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary small intestinal cancer accompanied by virchow lymph node metastasis undergoing TS-1 treatment].
  • Abdominal computed tomography (CT) revealed wall thickening of the small intestine and multiple lymph node metastases.
  • Barium meal study of the small intestine showed circular stenosis.
  • The patient was operated on under a diagnosis of tumor of the small intestine and left neck lymph node swelling.
  • Needle biopsy of the left neck lymph node and partial resection of the small intestine was done without regional lymph node dissection because of Virchow lymph node metastasis.
  • On the resected material a 5 x 4 cm type 2 tumor was identified.
  • Pathological findings included poorly-differentiated adenocarcinoma, si (bladder), n 4, P 0, ly 3, v 3, H 0, M(-), Stage IV.
  • The patient received the chemotherapy with TS-1.
  • TS-1(80 mg/body/day) orally administered for 4 weeks followed by a drug-free 2-week period as one course.
  • There were no drug side effects.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Intestinal Neoplasms / drug therapy. Intestine, Small. Lymph Nodes / pathology. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymphatic Metastasis. Neoadjuvant Therapy. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282734.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


15. Delaunoit T, Neczyporenko F, Limburg PJ, Erlichman C: Small bowel adenocarcinoma: a rare but aggressive disease. Clin Colorectal Cancer; 2004 Nov;4(4):241-8; discussion 249-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel adenocarcinoma: a rare but aggressive disease.
  • Unlike the colon and rectum, the small intestine is associated with a very low rate of tumor occurrence.
  • Regardless of the stage, surgery usually remains the cornerstone of small bowel adenocarcinoma therapy.
  • Because of the rarity of the disease, very few significant clinical trials have identified any efficient nonsurgical treatment; however, recent data indicate these tumors might be sensitive to chemotherapy alone or in association with radiation therapy.
  • We reviewed the clinical aspects of this rare but aggressive disease, focusing on new diagnostic procedures as well as on recent advances in their therapeutic management.
  • [MeSH-major] Adenocarcinoma. Intestinal Neoplasms. Intestine, Small
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnostic Imaging / methods. Digestive System Surgical Procedures. Endoscopy, Gastrointestinal / methods. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15555205.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 84
  •  go-up   go-down


16. Talamonti MS, Goetz LH, Rao S, Joehl RJ: Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg; 2002 May;137(5):564-70; discussion 570-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management.
  • HYPOTHESIS: This study was done to review the clinical presentation, surgical management, pathologic features, and prognostic factors for primary small-bowel cancers.
  • Significant prognostic predictors of overall survival for the entire cohort and for each tumor subtype included complete resection and American Joint Committee on Cancer tumor stage (P<.05).
  • Patient age, tumor location, histological grade, and use of chemotherapy and radiation therapy did not significantly influence survival.
  • The median time to recurrence was 16 months.
  • Twenty-one patients (16%) developed associated primary cancers.
  • Despite complete resections, patients with high-stage tumors remain at risk for recurrence.
  • [MeSH-minor] Actuarial Analysis. Adenocarcinoma / mortality. Adenocarcinoma / surgery. Carcinoid Tumor / mortality. Carcinoid Tumor / surgery. Female. Humans. Intestine, Small. Lymphoma / mortality. Lymphoma / surgery. Male. Middle Aged. Prognosis. Retrospective Studies. Sarcoma / mortality. Sarcoma / surgery. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11982470.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Moon YW, Rha SY, Shin SJ, Chang H, Shim HS, Roh JK: Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. J Cancer Res Clin Oncol; 2010 Mar;136(3):387-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators.
  • PURPOSE: Small bowel adenocarcinoma (SBA) is a rare malignancy with a poor outcome.
  • METHODS: Medical records of 100 patients with SBA were reviewed for clinical characteristics, treatment patterns, outcomes, and prognostic factors.
  • Seventy-four patients were diagnosed with stage III/IV disease (28/46 patients, respectively).
  • Of 34 R0/R1-resected patients, 16 received adjuvant chemotherapy.
  • Thirty-four patients with advanced SBA received palliative chemotherapy, showing a response rate of 27.6% and a median progression-free survival of 3.8 months.
  • In multivariate analysis, lower stage, nonduodenal location, and R0/R1 resection were good independent prognostic factors.
  • Distant metastasis as a dominant pattern of recurrence suggests a potential role for adjuvant chemotherapy.
  • Newer antitumor agents in advanced SBA should be evaluated considering the poor efficacy of current palliative chemotherapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Chemotherapy, Adjuvant / methods. Chemotherapy, Adjuvant / utilization. Digestive System Surgical Procedures / methods. Female. Humans. Intestine, Small / pathology. Korea. Male. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998 Aug;78(4):508-10 [9716035.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):66-71 [6691554.001]
  • [Cites] J Clin Oncol. 2009 Jun 1;27(16):2598-603 [19164203.001]
  • [Cites] Am J Surg. 1986 Jun;151(6):654-8 [2424326.001]
  • [Cites] Radiology. 2006 Dec;241(3):796-801 [17053201.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):183-8 [7842287.001]
  • [Cites] Surg Clin North Am. 1986 Aug;66(4):779-85 [3738698.001]
  • [Cites] Endoscopy. 2005 Oct;37(10):960-5 [16189768.001]
  • [Cites] Ann Surg. 2009 Jan;249(1):63-71 [19106677.001]
  • [Cites] Oncologist. 2005 Feb;10(2):132-7 [15709215.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2263-9 [17549572.001]
  • [Cites] Ann Surg Oncol. 1994 Jan;1(1):73-8 [7834432.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):225-31 [16755174.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Cancer Causes Control. 1993 Mar;4(2):163-9 [8481495.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Jpn J Clin Oncol. 2009 Jan;39(1):54-61 [18997182.001]
  • [Cites] Epidemiol Rev. 1986;8:1-27 [3533579.001]
  • [Cites] J Am Coll Surg. 1996 Aug;183(2):89-96 [8696551.001]
  • (PMID = 19760196.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


18. Bryan DN, Radbod R, Berek JS: An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):125-34
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer.
  • The objective of this study was to compare the treatment outcomes of surgical versus chemotherapeutic interventions for the management of intestinal obstruction secondary to metastatic epithelial ovarian cancer.
  • A retrospective analysis of 39 patients with epithelial ovarian cancer who had 98 events of intestinal obstruction was performed.
  • A medical records review of patients treated for advanced ovarian cancer from 1973 to 2003 was conducted.
  • Time from treatment to obstruction, complications, and predictors of outcome were analyzed.
  • Mean time from diagnosis of cancer to first obstruction was 38 months (range, 7-234 months).
  • Of 39 patients with obstruction, 5% were stage I, 2% stage II, 85% stage III, and 8% stage IV.
  • Prior to first obstruction, the median number of prior surgeries was 2 and chemotherapy regimens 3.
  • Sites of the 98 events of obstruction were small intestine, 79 (81%); large intestine, 8 (8%); and combined small and large intestines, 11 (11%).
  • The mean time to re-obstruction was 6.4 months (0-24) for chemotherapy, 5.1 months (0-40) for surgery, and 1.9 months (0-15) for supportive care.
  • The mean hospital stays were 7 days (2-10) for chemotherapy, 18 days (3-50) for surgery, and 7 days (0-20) for supportive care.
  • There were 4 major complications in the chemotherapy patients, 11 in the surgical patients, and 2 in the supportive only patients.
  • The only significant factor predictive of > or =6 month obstruction-free period was prior response to platinum-based chemotherapy.
  • Of the 13 patients with a response to chemotherapeutic or surgical treatment, 46% had an initial response to platinum-based chemotherapy, while 27% of 22 patients who re-obstructed in <6 months were platinum sensitive.
  • In this retrospective analysis of selected patients, surgery and chemotherapy were found to have similar outcomes.
  • The best predictor of either treatment's effectiveness is tumor sensitivity to platinum-based chemotherapeutic agents (P= 0.168).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colectomy / methods. Intestinal Neoplasms / secondary. Intestinal Obstruction / drug therapy. Intestinal Obstruction / surgery. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Palliative Care. Retrospective Studies. Risk Assessment. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445622.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. López-Cano M, Mañas MJ, Hermosilla E, Espín E: Multivisceral resection for colon cancer: analysis of prognostic factors. Dig Surg; 2010 Aug;27(3):238-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multivisceral resection for colon cancer: analysis of prognostic factors.
  • BACKGROUND/AIMS: To assess outcome of multivisceral resection in colon cancer patients and to identify predictors of survival.
  • METHODS: One hundred and thirteen consecutive patients with primary locally advanced colon cancer infiltrating adjacent organs undergoing multivisceral resection between 1998 and 2007 were reviewed.
  • Fifty-two patients had sigmoid tumors and 48 involvement of the small intestine.
  • Eighty-three patients received postoperative adjuvant therapy.
  • Hematochezia and adjuvant chemotherapy were independent factors of favorable outcome and grade G3 and tumor stage III-IV of poor survival.
  • CONCLUSION: Hematochezia and adjuvant chemotherapy were associated with a better survival, and poorly differentiated tumors and stage IV disease with a poor survival.
  • [MeSH-minor] Abdomen, Acute. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Gastrointestinal Hemorrhage / complications. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20571272.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


20. Rossi G, Marchioni A, Romagnani E, Bertolini F, Longo L, Cavazza A, Barbieri F: Primary lung cancer presenting with gastrointestinal tract involvement: clinicopathologic and immunohistochemical features in a series of 18 consecutive cases. J Thorac Oncol; 2007 Feb;2(2):115-20
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lung cancer presenting with gastrointestinal tract involvement: clinicopathologic and immunohistochemical features in a series of 18 consecutive cases.
  • BACKGROUND: Lung cancer initially manifesting as gastrointestinal (GI)-tract metastasis is exceedingly rare, representing a diagnostic challenge and a late-stage disease sign.
  • The clinicopathologic characteristics of the largest series of lung carcinomas initially presenting with GI involvement were described, focusing on differential diagnosis and therapeutic options.
  • METHODS: Eighteen consecutive cases of lung cancer (11 surgical specimens and 7 biopsies) initially diagnosed on GI histologic samples were identified during routine pathologist practice.
  • The small bowel was the most common GI involved site (12 cases), followed by the stomach (four) and large intestine (two).
  • Fourteen patients died shortly from disease (mean follow-up, 3 months); two are still alive with multiple metastases, and two patients with the GI tract as the unique site of metastasis underwent pulmonary lobectomy and chemotherapy and are alive without evidence of disease.
  • At morphology, there were 10 large cell undifferentiated carcinomas and eight adenocarcinomas.
  • CONCLUSION: Lung cancer presenting as GI-tract metastasis is probably more frequent than expected, and pathologists should always keep in mind this possibility when dealing with undifferentiated GI carcinoma.
  • Although GI metastasis from lung cancer is associated with dismal outcomes, pulmonary resection coupled with chemotherapy might represent a therapeutic option in selected patients with a solitary GI-tract metastasis.

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410025.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Fonteyne V, De Gersem W, De Neve W, Jacobs F, Lumen N, Vandecasteele K, Villeirs G, De Meerleer G: Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer. Int J Radiat Oncol Biol Phys; 2009 Nov 15;75(4):1013-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
  • PURPOSE: To determine the planning results and acute toxicity after hypofractionated intensity-modulated arc radiotherapy and androgen deprivation for lymph node metastasized (Stage N1) prostate cancer.
  • METHODS AND MATERIALS: A total of 31 patients with Stage T1-T4N1M0 prostate cancer were treated with intensity-modulated arc radiotherapy and 3 years of androgen deprivation as primary treatment.
  • A median dose of 69.3 Gy and 50 Gy was prescribed to the PTV(p) and PTV(e) respectively, to be delivered in 25 fractions.
  • Upper and lower gastrointestinal toxicity was scored using the Radiation Therapy Oncology Group toxicity and radiotherapy-induced lower intestinal toxicity scoring system.
  • Genitourinary toxicity was scored using a combined Radiation Therapy Oncology Group, LENT-SOMA (late effects normal tissue-subjective, objective, management, analytic), and Common Toxicity Criteria toxicity scoring system.
  • RESULTS: The median follow-up time was 3 months.
  • The mean prescription dose to the CTV(p) and PTV(p) was 70.4 Gy and 68.6 Gy, respectively.
  • The minimal dose to the CTV(e) and PTV(e) was 49.0 Gy and 47.0 Gy, respectively.
  • Fourteen patients developed acute Grade 2 lower gastrointestinal toxicity.
  • Acute Grade 3 and 2 genitourinary toxicity developed in 2 and 14 patients, respectively.
  • CONCLUSION: The results of our study have shown that hypofractionated intensity-modulated arc radiotherapy as primary therapy for N1 prostate cancer is feasible with low toxicity.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / adverse effects
  • [MeSH-minor] Aged. Dose Fractionation. Follow-Up Studies. Humans. Intestine, Large / radiation effects. Intestine, Small / radiation effects. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Neoplasm Staging. Prostate / radiation effects. Radiation Injuries / pathology. Radiotherapy Planning, Computer-Assisted. Seminal Vesicles / radiation effects. Tumor Burden. Urogenital System / radiation effects

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19386427.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists
  •  go-up   go-down


22. Tsuda H, Sekine K, Fujita K, Ligo M: Cancer prevention by bovine lactoferrin and underlying mechanisms--a review of experimental and clinical studies. Biochem Cell Biol; 2002;80(1):131-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer prevention by bovine lactoferrin and underlying mechanisms--a review of experimental and clinical studies.
  • In experimental studies, bovine lactoferrin (bLF) has been found to significantly inhibit colon, esophagus, lung, and bladder carcinogenesis in rats when administered orally in the post-initiation stage.
  • Marked increase in the number of cytotoxic T and NK cells in the mucosal layer of the small intestine and peripheral blood cells was thus found, this in turn enhancing the production of Interleukin 18 (IL-18) and caspase-1 in the epithelial cells of the small intestine, with possible consequent induction of interferon (IFN)-gamma positive cells.
  • More extensive clinical trials are now underway in the National Cancer Center Hospital and other institutes to further explore the preventive potential against colon carcinogenesis.
  • [MeSH-major] Lactoferrin / pharmacology. Lactoferrin / therapeutic use. Neoplasms / drug therapy. Neoplasms / prevention & control
  • [MeSH-minor] Animals. Antiviral Agents / therapeutic use. Clinical Trials as Topic. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Colonic Neoplasms / prevention & control. Hepatitis C, Chronic / drug therapy. Hepatitis C, Chronic / virology. Humans. Immunity, Mucosal / drug effects. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Neoplasm Metastasis / prevention & control. Pilot Projects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11908637.001).
  • [ISSN] 0829-8211
  • [Journal-full-title] Biochemistry and cell biology = Biochimie et biologie cellulaire
  • [ISO-abbreviation] Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antiviral Agents; EC 3.4.21.- / Lactoferrin
  • [Number-of-references] 35
  •  go-up   go-down


23. Li T, Ito K, Sumi S, Fuwa T, Horie T: Protective effect of aged garlic extract (AGE) on the apoptosis of intestinal epithelial cells caused by methotrexate. Cancer Chemother Pharmacol; 2009 Apr;63(5):873-80
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The side effects often disturb the cancer chemotherapy.
  • We previously reported that AGE protected the small intestine of rats from the MTX-induced damage.
  • In the present paper, the mechanism of the protection of AGE against the MTX-induced damage of small intestine was investigated, using IEC-6 cells originating from rat jejunum crypt.
  • IEC-6 cells in G2/M stage markedly decreased 72 h after the MTX treatment, which was preserved to the control level by the presence of AGE.
  • AGE may be useful for the cancer chemotherapy with MTX, since AGE reduces the MTX-induced intestinal damage.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Apoptosis / drug effects. Garlic. Intestinal Mucosa / drug effects. Intestine, Small / drug effects. Methotrexate / therapeutic use. Plant Extracts / pharmacology
  • [MeSH-minor] Animals. Blotting, Western. Caspase 3 / metabolism. Cell Proliferation / drug effects. Cells, Cultured. Cytochromes c / metabolism. Cytosol / drug effects. Cytosol / metabolism. Glutathione / metabolism. Mitochondria / drug effects. Mitochondria / metabolism. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677483.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Plant Extracts; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 3; GAN16C9B8O / Glutathione; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


24. Yu QS, Liu Y, Hou Y, Zhang F, Yi W, Wang X, Shuai J: [Effect of early intestinal dripping of jianpi tongli Chinese herbs on serum level IL-2, sIL-2R and IL-12 in patients with gastric cancer after operation]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Aug;25(8):710-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of early intestinal dripping of jianpi tongli Chinese herbs on serum level IL-2, sIL-2R and IL-12 in patients with gastric cancer after operation].
  • OBJECTIVE: To explore the regulation and clinical significance of intestinal dripping of Jianpi Tongli (JPTL) Chinese herbs on levels of serum cytokines, such as interleukin-2 (IL-2), soluble interleukin-2 receptor (sIL-2R) and interleukin-12 (IL-12) in treating patients with gastric cancer (GC) at early post-operational stage.
  • The medication was started from the 1st day after operation by intestinal dripping daily, 7 days as one course.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16152828.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Interleukin-2; 0 / Receptors, Interleukin-2; 187348-17-0 / Interleukin-12
  •  go-up   go-down


25. Mazaki T, Mado K, Manmoto J, Okame H, Ishii Y, Suzuki K, Masuda H, Takayama T: [Three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 combined with CPT- 11]. Gan To Kagaku Ryoho; 2008 Sep;35(9):1583-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 combined with CPT- 11].
  • We report three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 with CPT-11.
  • Case 1: A total gastrectomy was performed for a gastric cancer located in the lower to upper body of the stomach (T3 (SE), N2, H0, P0, por 2, stage III B).
  • Abdominal computed-tomography (CT) revealed a solitary liver metastasis in the S8 subsegment of the liver.
  • We treated the patient with S-1 combined with CPT-11.
  • Case 2: Sigmoidectomy and partial resection of small intestine and abdominal wall were performed for sigmoid colon cancer.
  • The intraoperative findings revealed liver metastases in left lobe of the liver (Si, N1, H1, P0, M0, tub 1, stage IV).
  • After surgery, the patient was treated with S-1 combined with CPT-11.
  • Case 3: Laparoscopic right hemicolectomy was performed for ascending colon cancer (SE, N1, H0, P0, M0, tub 1, stage III a).
  • We treated the patient with S-1 combined with CPT-11.
  • [MeSH-major] Camptothecin / analogs & derivatives. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Combinations. Female. Humans. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799916.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


26. Mimatsu K, Oida T, Kuboi Y, Kawasaki A, Kanou H, Kaneda H, Amano S: A long-surviving patient with unresectable advanced gastric cancer responding to S-1 after receiving improved gastrojejunostomy. Int J Clin Oncol; 2004 Jun;9(3):193-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-surviving patient with unresectable advanced gastric cancer responding to S-1 after receiving improved gastrojejunostomy.
  • Conventional gastrojejunostomy has been employed for unresectable advanced gastric cancer with pyloric stenosis; however, it is often not fully effective.
  • We report a patient with unresectable gastric cancer who was effectively treated with an anticancer drug, S-1, after receiving an improved gastrojejunostomy.
  • Preoperative findings were T3N2H0P0, stage III b.
  • At operation, the tumor was found to have invaded the duodenum and the head of the pancreas, and disseminated nodules were found in the mesenterium of the small intestine, the left diaphragm, and the round ligament of the liver.
  • A curative operation was impossible for the advanced gastric cancer.
  • She started treatment with 80 mg/day of S-1, given orally, for 28 days, followed by 14 days' rest, as 1 course.
  • During 16 courses of the treatment, she maintained a performance status of 0 to 1 and maintained quality of life.
  • This case suggested that the improved gastrojejunostomy was a useful method for treating unresectable gastric cancer, allowing the possibility of oral intake, and the use of S-1.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Anastomosis, Surgical. Drug Combinations. Female. Humans. Jejunum / surgery. Middle Aged. Palliative Care. Stomach / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15221605.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


27. Brooks S, Bownes P, Lowe G, Bryant L, Hoskin PJ: Cervical brachytherapy utilizing ring applicator: comparison of standard and conformal loading. Int J Radiat Oncol Biol Phys; 2005 Nov 1;63(3):934-9
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Afterloading high-dose-rate brachytherapy (HDR) treatment of cervical cancer with cross-sectional imaging and three-dimensional (3D) reconstruction offers opportunities for individualized conformal treatment planning rather than fixed point-A dosimetry.
  • METHODS AND MATERIALS: Between June 2003 and September 2004, 15 patients with FIGO Stage 1B-4A cervical carcinoma, median age 56 years, were treated with radical external-beam radiotherapy to pelvis, including paraortic nodes if positive on staging investigations.
  • Fourteen patients received concurrent cisplatin chemotherapy.
  • Clinical target volume (CTV) and organs at risk (OAR)--rectum, bladder, and small bowel--were outlined from postinsertion CT planning scans.
  • A standard plan was produced that delivered 6 Gy to point A, and a second plan delivered 6 Gy to PTV.
  • Constraints were defined for the OAR: bladder, 6 Gy; rectum, 5 Gy; and small bowel, 5 Gy.
  • RESULTS: Mean COIN values were 0.39 for conformal plans and 0.33 for standard plans (p = 0.001); mean D95 values were 4.79 Gy and 4.50 Gy, respectively.
  • CONCLUSION: The majority of patients achieved a plan closer to ideal for coverage of PTV, with minimization of radiation received by normal tissues for conformal loading measured by COIN compared with fixed point-A prescription that used the cervical ring applicator.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Carcinoma, Squamous Cell / radiotherapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Intestine, Small / radiation effects. Middle Aged. Radiation Injuries / prevention & control. Rectum / radiation effects. Urinary Bladder / radiation effects

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16199322.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Ogawa M, Takao Y, Mukai H, Satou K, Anazawa S, Yamazaki Y, Aoki T: [A case report of effective chemoradiation with 5'-DFUR and concomitant preoperative radiotherapy of the lower rectum]. Gan To Kagaku Ryoho; 2002 Apr;29(4):619-23
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We treated a lower rectal carcinoma patient with preoperative radiation and chemotherapy, resulting in a downstaging, and the findings are reported herein.
  • Preoperative radiation and chemotherapy included whole pelvis irradiation (44 Gy in total) and 800 mg/day of 5'-DFUR administered until one day before the operation.
  • During the operation, we found serositis of the small intestine and retroperitoneal fibrosis thought to be due to the irradiation.
  • Histopathologic findings showed: invasion degree, sm2; stage I with N0; and histologic grading, Grade 2.
  • At present, in Europe and the USA, large scale studies are being conducted to evaluate preoperative radiation and chemotherapy in patients with lower rectal carcinoma.
  • We think that this therapy is an effective treatment, since a distance (AW) from the lower margin of the tumor and the cut edge of the anal end can be established.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antimetabolites, Antineoplastic / administration & dosage. Floxuridine / administration & dosage. Preoperative Care. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Drug Administration Schedule. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11977551.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 039LU44I5M / Floxuridine; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


29. Morsi A, Abd El-Ghani Ael-G, El-Shafiey M, Fawzy M, Ismail H, Monir M: Clinico-pathological features and outcome of management of pediatric gastrointestinal lymphoma. J Egypt Natl Canc Inst; 2005 Dec;17(4):251-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The purpose of this study is to evaluate pediatric GIT lymphomas as regards clinico-pathological features, controversies in surgical treatment, role of chemotherapy and the prognostic features.
  • The data of every patient included: Age, sex, presenting symptoms and signs, preoperative investigations, extent of the disease at diagnosis and the type of resection performed, histopathological examination, details of chemotherapy and state at follow up.
  • The lesions were located in the small intestine (n=15), the large intestine (n=14), the ileocecal region (n=10), stomach (n=2), and multifocally (n=2).
  • Burkitt's lymphoma was the commonest histological type (n=24).
  • The majority were stage IIE and IIIE (22 and 17 respectively).
  • All patients received a sort of systemic chemotherapy.
  • The only parameters that had significantly affected the overall survival were localized disease, complete resection, earlier stage and response to chemotherapy with p values, (0.005, 0.001, 0.005 and <0.001 respectively).
  • Chemotherapy represents a cornerstone in the treatment and offers an excellent chance for long term, disease free survival.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / therapy. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Combined Modality Therapy. Digestive System Surgical Procedures. Disease-Free Survival. Female. Humans. Infant. Male. Neoplasm Staging. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17102814.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


30. Temmim L, Baker H, Amanguno H, Madda JP, Sinowatz F: Clinicopathological features of extranodal lymphomas: Kuwait experience. Oncology; 2004;67(5-6):382-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 935 patients with extranodal non-Hodgkin lymphoma (NHL) diagnosed in the period between January 1985 and December 2000 in Kuwait Cancer Center, serving the whole population of Kuwait, were used to describe the clinicopathological and epidemiological features of extranodal lymphomas in Kuwait.
  • Extranodal lymphomas accounted for 45% of all NHL observed during this time.
  • All NHL cases from Kuwait Cancer registry were analyzed and pathologically reclassified using the latest WHO (2000) classification.
  • The most common lymphoma observed was diffuse large B-cell lymphoma (58.60%) followed by Burkitt s lymphoma (BL) (3.80%).
  • The most common extranodal sites were stomach (19.70%) and skin (17.80%) in the adult group, large intestine (29.80%) and small intestine (19.30%) in the pediatric age group.
  • The majority (73.40%) of adult extranodal lymphomas was in stage IE-IIE and had a very good prognosis.
  • On the contrary, the majority of pediatric extranodal lymphomas were found to be in stage III and IV.
  • Variations in treatment policies (single agent or combined chemotherapy, radiotherapy, combined modality treatment) adopted and changed during the time period of 16 years of this retrospective study were documented.
  • [MeSH-minor] Adolescent. Adult. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. Female. Humans. Infant. Intestinal Neoplasms / epidemiology. Intestinal Neoplasms / pathology. Kuwait / epidemiology. Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Registries. Retrospective Studies. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology. Stomach Neoplasms / epidemiology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel
  • (PMID = 15713994.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


31. Paulino AC, Wen BC, Brown CK, Tannous R, Mayr NA, Zhen WK, Weidner GJ, Hussey DH: Late effects in children treated with radiation therapy for Wilms' tumor. Int J Radiat Oncol Biol Phys; 2000 Mar 15;46(5):1239-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late effects in children treated with radiation therapy for Wilms' tumor.
  • PURPOSE: To determine the frequency and types of late effects in children receiving radiation therapy (RT) for Wilms' tumor.
  • MATERIALS AND METHODS: From 1968 to 1994, 55 children received megavoltage RT at our institution as part of treatment for Wilms' tumor.
  • There were 12 Stage I, eight Stage II, 15 Stage III, six Stage IV, and one Stage V patient.
  • All patients received chemotherapy; the most common agents were actinomycin-D/vincristine/adriamycin in 13 and actinomycin-D/vincristine in 18.
  • RESULTS: Of 42 patients, 13 (31.0%) did not have late effects of treatment.
  • The number of patients who developed muscular hypoplasia, limb length inequality, kyphosis, and iliac wing hypoplasia were seven (16.7%), five (11.9%), three (7.1%), and three (7.1%), respectively.
  • Median time to development of scoliosis was 102 months, with a range of 16-146 months.
  • Only one of 12 Group A patients developed scoliosis.
  • Of 23 patients, five irradiated within 10 days of surgery and one of 19 irradiated after 10 days developed bowel obstruction (p = 0.09, log rank test).
  • Three patients developed hypertension with normal blood urea nitrogen (BUN) and creatinine levels; another patient had chronic renal insufficiency in a nonirradiated kidney.
  • One patient developed diffuse interstitial pneumonitis.
  • Four patients developed benign neoplasms; three were in the RT field (two osteochondroma, one lipoma) and one outside (cervical intraepithelial neoplasia II).
  • There were three second malignancies (chronic myelogenous leukemia at 9 years, osteosarcoma at 11 years, and breast cancer at 25 years after initial diagnosis of nephroblastoma); both solid malignancies occurred in the RT field.
  • CONCLUSIONS: Late effects of therapy were seen in more than two thirds of children treated for Wilms' tumor.
  • [MeSH-minor] Child. Child, Preschool. Dose-Response Relationship, Radiation. Female. Fertility / radiation effects. Follow-Up Studies. Humans. Infant. Intestinal Obstruction / etiology. Intestine, Small / radiation effects. Kidney Diseases / etiology. Kyphosis / etiology. Male. Muscles / radiation effects. Neoplasm Staging. Neoplasms, Second Primary / etiology. Puberty, Delayed / etiology. Scoliosis / etiology. Time Factors

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10725637.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


32. Saibishkumar EP, Patel FD, Sharma SC: Results of radiotherapy alone in the treatment of carcinoma of uterine cervix: a retrospective analysis of 1069 patients. Int J Gynecol Cancer; 2005 Sep-Oct;15(5):890-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of radiotherapy alone in the treatment of carcinoma of uterine cervix: a retrospective analysis of 1069 patients.
  • This retrospective study was made to analyze our results of radiotherapy alone in the treatment of carcinoma cervix.
  • The median dose to point A was 81 Gy.
  • On multivariate analysis, bulk, overall treatment time (OTT) and response to EBRT were found to affect OS and DFS independently.
  • Similarly, OTT, response to EBRT, stage, and age were the factors that influenced pelvic control.
  • Incidence of severe late toxicities (grade 3/4) in the rectum, bladder, small intestine, and skin were 1.1%, 1.2%, 0.2%, and 1.2%, respectively.
  • The addition of chemotherapy may be beneficial in patients with adverse prognostic factors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brachytherapy. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174241.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement